Self-reported implant-site inflammatory reactions after COVID-19 vaccination among Indonesian cosmetic implant recipients: Cross-sectional survey
Journal of Pharmacy & Pharmacognosy Research · 01.07.2026 · 14 (4) · 2722
DOI: 10.56499/jppres_14.4.2722 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Pharmacy & Pharmacognosy Research, online erschienen am 01.07.2026. Verfasst von Ago Harlim und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Context
Delayed inflammatory reactions at cosmetic implant sites have been reported after coronavirus disease 2019 vaccination, but population-level data from Indonesia remain limited.
Aims
To estimate the prevalence of self-reported implant-site inflammatory reactions after coronavirus disease 2019 vaccination among cosmetic implant users in Indonesia and to explore associated factors.
Methods
A cross-sectional online survey was distributed in Indonesia from November 2021 to July 2022. Respondents receiving at least one coronavirus disease 2019 vaccine dose who reported having a cosmetic implant were included. The primary outcome was self-reported localized redness, swelling, or pain at the implant site rather than clinically verified foreign-body reaction.
Results
Among 1,610 valid responses, 266 respondents reported having cosmetic implants. Implant-site inflammatory reactions were reported by 10 respondents, corresponding to a period prevalence of 3.76% (95% CI: 1.82–6.80%). Adverse vaccine reactions were reported by 91 respondents (34.2%). An exploratory analysis suggested these respondents had higher odds of implant-site inflammatory reactions (OR: 4.78; 95% CI: 1.21–18.94; p = 0.04). However, this finding must be interpreted cautiously because only 10 events were observed and multivariable adjustment was not possible. No significant association was observed with age, sex, or vaccine type.
Conclusions
A small proportion of respondents with cosmetic implants reported implant-site inflammatory symptoms following coronavirus disease 2019 vaccination. Because outcomes were self-reported, derived from a cross-sectional design, and key confounders were unmeasured, causal interpretation remains uncertain. These findings should be interpreted strictly as hypothesis-generating pharmacovigilance evidence. Prospective, clinically validated studies incorporating detailed implant characterization and reaction timing are required.
Zitieren
APA
Harlim, A., Panjaitan, H., Andrew, H., & Harlim, C. (2026). Self-reported implant-site inflammatory reactions after COVID-19 vaccination among Indonesian cosmetic implant recipients: Cross-sectional survey. Journal of Pharmacy & Pharmacognosy Research, 14(4), 2722. https://doi.org/10.56499/jppres_14.4.2722
Vancouver
Harlim A, Panjaitan H, Andrew H, Harlim C. Self-reported implant-site inflammatory reactions after COVID-19 vaccination among Indonesian cosmetic implant recipients: Cross-sectional survey. Journal of Pharmacy & Pharmacognosy Research. 2026;14(4):2722. doi:10.56499/jppres_14.4.2722
BibTeX
@article{Harlim2026,
author = {Harlim, Ago and Panjaitan, Hulman and Andrew, Hubert and Harlim, Chastine},
title = {Self-reported implant-site inflammatory reactions after COVID-19 vaccination among Indonesian cosmetic implant recipients: Cross-sectional survey},
journal = {Journal of Pharmacy & Pharmacognosy Research},
year = {2026},
volume = {14},
number = {4},
pages = {2722},
doi = {10.56499/jppres_14.4.2722}
}
EUVIMED